Genesys, AmorChem lead $7 mln Series A funding of Inversago
Montréal-based preclinical-stage biotechnology company Inversago Pharma Inc has raised $7 million in a Series A financing. The round was led by Canadian life sciences investors Genesys Capital and AmorChem. They were joined by JDRF T1D Fund, Accel-Rx, Anges Québec Capital, Anges Québec, Tarnagulla Ventures and several angel investors. Inversago, founded in 2015 by CEO François Ravenelle, is developing new generations of cannabinoid-1 receptor (CB1) inverse agonists for the treatment of Prader-Willi Syndrome, type 1 diabetes, obesity and other metabolic disorders. The company will use the funds raised for its development plan and to advance its CB1 platform.
25 July 2018•4 mins read
